A significant prevalence of venous thromboembolism and CVD (cardiovascular disease) is the major factor in promoting the growth of the global heparin market. In 2018, the Centre for Disease Control and Prevention (CDC ) published a report in which it stated that more than 900,000 people only in the US are affected by deep vein thrombosis and pulmonary embolism every year. More than 18 million people die across the globe due to cardiovascular disorder this shows an immense opportunity for the heparin market to grow as heparin is the primary drug used as an anticoagulant used to prevent blood clotting.
To Request a Sample of our Report on Heparin Market: https://www.omrglobal.com/request-sample/heparin-market
Heart diseases such as CVD and stroke; among other heart diseases are the leading causes of mortalities across the globe. According to the CDC, every 40 seconds, an individual in the US has a heart attack. In addition, around 805,000 Americans have a heart attack every year. According to the WHO, around 17.9 million fatalities occur due to CVD in 2016, representing around 31% of global fatalities. Amongst these fatalities, around 7.4 million were due to CHD and approximately 6.7 million were due to stroke. By 2030, it has been projected that CVDs would be responsible for approximately 23.6 million mortalities across the globe. This growing prevalence of CVD induced the demand for the anticoagulant drug which will contribute to the heparin market.
Various players are receiving FDA approval for their new heparin drug formulas which will contribute to the global heparin market in the near future. For instance, in April 2019, B. Braun Medical Inc. announced its launch of Heparin Sodium Injection, USP. It is an FDA approved and first of its kind syringe with attached needle for subcutaneous and intravenous use. It is designed with an aim to provide their patients with a better treatment experience with reduced risk of errors and expanding its product portfolio in the US in the medical field.
(Get 15% Discount on Buying this Report)
A full Report of Heparin Market is Available at: https://www.omrglobal.com/industry-reports/heparin-market
Global Heparin Market Segmentation
By Product
- Unfractionated Heparin
- Ultra-Low Molecular Weight Heparin (ULMWH)
- Low molecular weight Heparin (LMWH)
By Route of Administration
- Intravenous
- Subcutaneous
By Application
- Atrial Fibrillation & Heart Attack
- Coronary Heart Disease
- Pulmonary Embolism (PE)
- Deep Vein Thrombosis (DVT)
- Others
Global Heparin Market – Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of The World
Company Profiles
- B Barun Melsungen AG
- Baxter International Inc.
- Eisai Co. Ltd.
- F. Hoffman-La Roche Ltd.
- Fresenius Kabi AG
- GlaxoSmithKline plc
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
- Hikma Pharmaceuticals PLC
- Leo Pharma A/S
- Mylan N.V.
- Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
- Novartis AG
- Opocrin S.P.A
- Pfizer Inc.
- Sanofi S.A.
- Syntex S.A.
Reasons for Buying from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/heparin-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit Orion Market Research
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
